Prognostic factors in metastatic gastric carcinoma
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-2.13283Ключові слова:
chemotherapy, gastric cancer, metastasis, prognostic factors, survivalАнотація
Summary. Although its incidence has declined over last half-century, gastric cancer remains the second most frequent cause of cancer death in the world. The ⅔ of the patients are metastatic at diagnosis. The current study aimed to identify some determinants of survival in patients with metastatic gastric carcinoma. Materials and Methods: It was a retrospective study that involved 49 patients treated with palliative chemotherapy between January 2000 and December 2010. Factors included: age, gender, performance status, metastatic diagnosis onset (at diagnosis or later); specific metastatic sites, number of metastatic localizations, response to chemotherapy, and hemoglobin rate. Results: In univariate analysis, factors associated to a better survival were: metastasis at diagnosis, good performance status, response to chemotherapy and single metastatic site. Independent factors in multivariate analysis were: metastasis at diagnosis and single metastatic site. Conclusion: Our study confirmed many determinants on survival described in the literature.
Посилання
Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 200. Int J Cancer 2010; 127: 2893–917.
Hsairi M, Fakfakh R, Ben Abdallah M, et al. Assessment of cancer incidence in Tunisia. La Tunis Med 2002; 80: 57–64.
Kanagavel D, Pokataev IA, Fedyanin MY, et al. A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy. Ann Oncol 2010; 21: 1779–85.
Yoshida M, Ohtsu A, Boku N, et al. Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan clinical oncology group (JCOG) Study. Jpn J Clin Oncol 2004; 34: 654–9.
Blank S, Lordick F, Dobritz M, et al. A reliable risk score for stage IV sophagogastric cancer. EJSO 2013; 39: 823–30.
Rivera F, Vega-Villegas ME, Lopez-Brea MF. Chemotherapy of advanced gastric cancer. Cancer Treat Rev 2007; 33: 315–24.
Power D, Kelsen DP, Shah MA. Advanced gastric cancer — Slow but steady progress. Cancer Treat Rev 2010; 36: 384–92.
D’Angelica M, Gonen M, Brennan MF, et al. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004; 240: 808–16.
Chau I, Norman AR, Cunningham D, et al. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer — pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 2004; 22: 2395–403.
Kunisaki C, Makino H, Takagawai R, et al. Impact of palliative gastrectomy in patients with incurable advanced gastric cancer. Anticancer Res 2008; 28: 1309–16.
Kulig P, Sierzega M, Kowalczyk T, et al. Non-curative gastrectomy for metastatic gastric cancer: Rationale and long-term outcome in multicenter settings. EJSO 2012; 38: 490–6.
Lin YC, Liu HE, Wang CH, et al. Clinical benefit and response in patients with gastric cancer to weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and leucovorin (LV). Anticancer Res 1999; 19: 5615–20.
MacDonald JS, Schein PS, Woolley PV, et al. 5-Fluorouracil, Doxorubicin, and Mitomycine (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 1980; 93: 533–6.
##submission.downloads##
Опубліковано
Як цитувати
Номер
Розділ
Ліцензія
Авторське право (c) 2023 Експериментальна онкологія
Ця робота ліцензується відповідно до Creative Commons Attribution-NonCommercial 4.0 International License.
